National Amyloidosis Centre Patient Forum

Amyloidosis => Research => Topic started by: georgeturner on April 20, 2016, 08:42:58 pm

Title: Alnylam Patisiran Trial for Hereditay ATTR with FAP
Post by: georgeturner on April 20, 2016, 08:42:58 pm
Complete 18-Month Data from Ongoing Phase 2 OLE Study with Patisiran in Development for the Treatment of Hereditary TTR-Mediated Amyloidosis with Polyneuropathy (hATTR-PN).

http://www.alnylam.com/capella/presentations/complete-18-month-ph-2-ole-data-from-patisiran/
Title: Re: Alnylam Patisiran Trial for Hereditay ATTR with FAP
Post by: Roger Curlett on April 24, 2016, 09:57:09 pm
Cheers George, hopefully we'll all have access to this drug once it's available post trials.
Title: Re: Alnylam Patisiran Trial for Hereditay ATTR with FAP
Post by: georgeturner on April 25, 2016, 10:09:48 am
Roger,

With the trials of ALNYLAM's Patisiran and Revusiran along IONIS TTR RX all showing promising results, it's looking much more hopeful for ATTR patients. It takes a lot of time, but let's hope they are approved and become available soon.